Butterfly Network vs Insilico Medicine

By valuation, Butterfly Network is the larger company at $1.5B versus $1.2B — a 1.3x difference. Size can also be measured by team: Butterfly Network employs 500-1000 people while Insilico Medicine has 350 employees.

Butterfly Network has raised more in total funding at $700M, compared to Insilico Medicine's $403M — a gap of $297M. Combined, the two companies have completed 3 known funding rounds.

Butterfly Network holds the higher Awaira Score at 85/100, compared to Insilico Medicine's 67/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 18-point gap that reflects meaningful differences in scale or traction.

Butterfly Network was founded by John Martin in 2011. Insilico Medicine was founded by Alex Zhavoronkov in 2014. Visit each company's profile on Awaira for a full founder biography.

Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. Insilico Medicine: Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company leverages artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular properties, identify disease targets, and design novel compounds with improved efficacy and reduced toxicity. The company operates across several segments: AI-powered target identification, lead optimization, and clinical trial optimization. Notable applications include oncology, aging-related diseases, and fibrosis. Insilico Medicine has demonstrated its technology through partnerships with pharmaceutical companies and biotech firms seeking to reduce drug development timelines and costs. The platform has been applied to various disease targets, with some candidates advancing through development stages. With $403 million in total funding and a valuation of $1.2 billion, Insilico Medicine represents a significant player in the AI healthcare sector. The company went public, reflecting investor confidence in its technology platform and business model. Its competitive position centers on the integration of generative AI models with molecular biology expertise. The company competes alongside other AI drug discovery platforms while differentiating through its aging research focus and established pharma partnerships. Insilico Medicine uniquely combines generative AI with longevity research, targeting age-related diseases while maintaining traditional pharma collaboration channels.

Butterfly Network was founded first in 2011, giving it 3 years of additional market experience. Insilico Medicine was founded later in 2014. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Butterfly Network has approximately 500-1000 employees, while Insilico Medicine has approximately 350. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Butterfly Network and Insilico Medicine are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.